AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Boundless Bio, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Jonathan E. Lim of Boundless Bio received a stock option grant on June 23, 2025, representing a significant insider transaction. The key details include:

  • Granted 24,000 stock options to purchase common stock
  • Exercise price set at $1.03 per share
  • Options expire on June 22, 2035
  • Vesting schedule: Equal monthly installments over 12 months through June 23, 2026
  • Accelerated vesting provision if next annual stockholder meeting occurs before June 23, 2026

The grant was executed under direct ownership, with Jessica Oien signing as attorney-in-fact. This equity compensation aligns with standard director compensation practices and demonstrates the company's commitment to retaining board talent through long-term incentives.

Il direttore Jonathan E. Lim di Boundless Bio ha ricevuto una concessione di opzioni su azioni il 23 giugno 2025, rappresentando una significativa transazione interna. I dettagli principali sono:

  • Concessione di 24.000 opzioni su azioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a $1,03 per azione
  • Scadenza delle opzioni il 22 giugno 2035
  • Programma di maturazione: rate mensili uguali per 12 mesi fino al 23 giugno 2026
  • Clausola di maturazione accelerata se l'assemblea annuale degli azionisti successiva si tiene prima del 23 giugno 2026

La concessione è stata eseguita sotto proprietà diretta, con Jessica Oien che ha firmato come procuratore. Questa forma di compenso azionario è in linea con le pratiche standard per i direttori e dimostra l'impegno dell'azienda a trattenere i talenti del consiglio attraverso incentivi a lungo termine.

El director Jonathan E. Lim de Boundless Bio recibió una concesión de opciones sobre acciones el 23 de junio de 2025, representando una transacción importante de información privilegiada. Los detalles clave incluyen:

  • Otorgadas 24,000 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $1.03 por acción
  • Las opciones expiran el 22 de junio de 2035
  • Calendario de adquisición: cuotas mensuales iguales durante 12 meses hasta el 23 de junio de 2026
  • Disposición de adquisición acelerada si la próxima reunión anual de accionistas ocurre antes del 23 de junio de 2026

La concesión se ejecutó bajo propiedad directa, con Jessica Oien firmando como apoderada. Esta compensación en acciones está alineada con las prácticas estándar para directores y demuestra el compromiso de la empresa de retener el talento del consejo mediante incentivos a largo plazo.

Boundless Bioì� ì´ì‚¬ Jonathan E. Limì€ 2025ë…� 6ì›� 23ì¼ì— ì£¼ì‹ ë§¤ìˆ˜ ì„ íƒê¶Œì„ ë¶¶Ä여받ì•� 중요í•� ë‚´ë¶€ìž� 거래ë¥� 나타냈습니다. 주요 ë‚´ìš©ì€ ë‹¤ìŒê³� 같습니다:

  • 보통주를 매수í•� ìˆ� 있는 24,000ì£� 주ì‹ë§¤ìˆ˜ì„ íƒê¶� ë¶¶Äì—�
  • í–‰ì‚¬ê°€ê²©ì€ ì£¼ë‹¹ $1.03ë¡� 설정
  • 옵션 만료ì¼ì€ 2035ë…� 6ì›� 22ì�
  • 베스íŒ� ì¼ì •: 2026ë…� 6ì›� 23ì¼ê¹Œì§€ 12개월 ë™ì•ˆ 매월 ë™ì¼í•� í• ë¶€ë¡� 베스íŒ�
  • 2026ë…� 6ì›� 23ì� ì´ì „ì—� ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒê°€ 열릴 경우 ê°€ì†� 베스íŒ� ì¡°í•­ ì ìš©

ì� ë¶¶Ä여는 ì§ì ‘ 소유ê¶� í•˜ì— ì´ë£¨ì–´ì¡Œìœ¼ë©°, Jessica Oienì� 법정대리ì¸ìœ¼ë¡œ 서명했습니다. ì� ì£¼ì‹ ë³´ìƒì€ ì´ì‚¬ ë³´ìƒ ê´€í–‰ì— ë¶€í•©í•˜ë©�, 회사가 장기 ì¸ì„¼í‹°ë¸Œë¥� 통해 ì´ì‚¬íš� ì¸ìž¬ë¥� 유지하려ëŠ� ì˜ì§€ë¥� ë³´ì—¬ì¤ë‹ˆë‹�.

Le directeur Jonathan E. Lim de Boundless Bio a reçu une attribution d'options d'achat d'actions le 23 juin 2025, constituant une transaction importante d'initié. Les détails clés sont les suivants :

  • Attribution de 24 000 options d'achat pour acquérir des actions ordinaires
  • Prix d'exercice fixé à 1,03 $ par action
  • Expiration des options le 22 juin 2035
  • Calendrier d'acquisition : versements mensuels égaux sur 12 mois jusqu'au 23 juin 2026
  • Clause d'acquisition accélérée si la prochaine assemblée générale annuelle des actionnaires a lieu avant le 23 juin 2026

L'attribution a été réalisée sous propriété directe, Jessica Oien signant en tant que mandataire. Cette rémunération en actions est conforme aux pratiques standard des administrateurs et illustre l'engagement de la société à fidéliser les talents du conseil par des incitations à long terme.

Direktor Jonathan E. Lim von Boundless Bio erhielt am 23. Juni 2025 eine Gewährung von Aktienoptionen, was eine bedeutende Insidertransaktion darstellt. Die wichtigsten Details sind:

  • Gewährung von 24.000 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis festgelegt auf $1,03 pro Aktie
  • Optionsablauf am 22. Juni 2035
  • Vesting-Zeitplan: Gleichmäßige monatliche Raten über 12 Monate bis zum 23. Juni 2026
  • Beschleunigte Vesting-Klausel, falls die nächste jährliche Hauptversammlung vor dem 23. Juni 2026 stattfindet

Die Gewährung erfolgte unter direktem Eigentum, wobei Jessica Oien als Bevollmächtigte unterschrieb. Diese Aktienvergütung entspricht den üblichen Vergütungspraktiken für Direktoren und zeigt das Engagement des Unternehmens, durch langfristige Anreize Vorstandsmitglieder zu binden.

Positive
  • None.
Negative
  • None.

Il direttore Jonathan E. Lim di Boundless Bio ha ricevuto una concessione di opzioni su azioni il 23 giugno 2025, rappresentando una significativa transazione interna. I dettagli principali sono:

  • Concessione di 24.000 opzioni su azioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a $1,03 per azione
  • Scadenza delle opzioni il 22 giugno 2035
  • Programma di maturazione: rate mensili uguali per 12 mesi fino al 23 giugno 2026
  • Clausola di maturazione accelerata se l'assemblea annuale degli azionisti successiva si tiene prima del 23 giugno 2026

La concessione è stata eseguita sotto proprietà diretta, con Jessica Oien che ha firmato come procuratore. Questa forma di compenso azionario è in linea con le pratiche standard per i direttori e dimostra l'impegno dell'azienda a trattenere i talenti del consiglio attraverso incentivi a lungo termine.

El director Jonathan E. Lim de Boundless Bio recibió una concesión de opciones sobre acciones el 23 de junio de 2025, representando una transacción importante de información privilegiada. Los detalles clave incluyen:

  • Otorgadas 24,000 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $1.03 por acción
  • Las opciones expiran el 22 de junio de 2035
  • Calendario de adquisición: cuotas mensuales iguales durante 12 meses hasta el 23 de junio de 2026
  • Disposición de adquisición acelerada si la próxima reunión anual de accionistas ocurre antes del 23 de junio de 2026

La concesión se ejecutó bajo propiedad directa, con Jessica Oien firmando como apoderada. Esta compensación en acciones está alineada con las prácticas estándar para directores y demuestra el compromiso de la empresa de retener el talento del consejo mediante incentivos a largo plazo.

Boundless Bioì� ì´ì‚¬ Jonathan E. Limì€ 2025ë…� 6ì›� 23ì¼ì— ì£¼ì‹ ë§¤ìˆ˜ ì„ íƒê¶Œì„ ë¶¶Ä여받ì•� 중요í•� ë‚´ë¶€ìž� 거래ë¥� 나타냈습니다. 주요 ë‚´ìš©ì€ ë‹¤ìŒê³� 같습니다:

  • 보통주를 매수í•� ìˆ� 있는 24,000ì£� 주ì‹ë§¤ìˆ˜ì„ íƒê¶� ë¶¶Äì—�
  • í–‰ì‚¬ê°€ê²©ì€ ì£¼ë‹¹ $1.03ë¡� 설정
  • 옵션 만료ì¼ì€ 2035ë…� 6ì›� 22ì�
  • 베스íŒ� ì¼ì •: 2026ë…� 6ì›� 23ì¼ê¹Œì§€ 12개월 ë™ì•ˆ 매월 ë™ì¼í•� í• ë¶€ë¡� 베스íŒ�
  • 2026ë…� 6ì›� 23ì� ì´ì „ì—� ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒê°€ 열릴 경우 ê°€ì†� 베스íŒ� ì¡°í•­ ì ìš©

ì� ë¶¶Ä여는 ì§ì ‘ 소유ê¶� í•˜ì— ì´ë£¨ì–´ì¡Œìœ¼ë©°, Jessica Oienì� 법정대리ì¸ìœ¼ë¡œ 서명했습니다. ì� ì£¼ì‹ ë³´ìƒì€ ì´ì‚¬ ë³´ìƒ ê´€í–‰ì— ë¶€í•©í•˜ë©�, 회사가 장기 ì¸ì„¼í‹°ë¸Œë¥� 통해 ì´ì‚¬íš� ì¸ìž¬ë¥� 유지하려ëŠ� ì˜ì§€ë¥� ë³´ì—¬ì¤ë‹ˆë‹�.

Le directeur Jonathan E. Lim de Boundless Bio a reçu une attribution d'options d'achat d'actions le 23 juin 2025, constituant une transaction importante d'initié. Les détails clés sont les suivants :

  • Attribution de 24 000 options d'achat pour acquérir des actions ordinaires
  • Prix d'exercice fixé à 1,03 $ par action
  • Expiration des options le 22 juin 2035
  • Calendrier d'acquisition : versements mensuels égaux sur 12 mois jusqu'au 23 juin 2026
  • Clause d'acquisition accélérée si la prochaine assemblée générale annuelle des actionnaires a lieu avant le 23 juin 2026

L'attribution a été réalisée sous propriété directe, Jessica Oien signant en tant que mandataire. Cette rémunération en actions est conforme aux pratiques standard des administrateurs et illustre l'engagement de la société à fidéliser les talents du conseil par des incitations à long terme.

Direktor Jonathan E. Lim von Boundless Bio erhielt am 23. Juni 2025 eine Gewährung von Aktienoptionen, was eine bedeutende Insidertransaktion darstellt. Die wichtigsten Details sind:

  • Gewährung von 24.000 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis festgelegt auf $1,03 pro Aktie
  • Optionsablauf am 22. Juni 2035
  • Vesting-Zeitplan: Gleichmäßige monatliche Raten über 12 Monate bis zum 23. Juni 2026
  • Beschleunigte Vesting-Klausel, falls die nächste jährliche Hauptversammlung vor dem 23. Juni 2026 stattfindet

Die Gewährung erfolgte unter direktem Eigentum, wobei Jessica Oien als Bevollmächtigte unterschrieb. Diese Aktienvergütung entspricht den üblichen Vergütungspraktiken für Direktoren und zeigt das Engagement des Unternehmens, durch langfristige Anreize Vorstandsmitglieder zu binden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lim Jonathan E

(Last) (First) (Middle)
C/O BOUNDLESS BIO, INC.
10955 ALEXANDRIA WAY, SUITE 100

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Boundless Bio, Inc. [ BOLD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $1.03 06/23/2025 A 24,000 (1) 06/22/2035 Common Stock 24,000 $0 24,000 D
Explanation of Responses:
1. The stock option shall vest in substantially equal monthly installments over the 12 months following June 23, 2025 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 23, 2026, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.
/s/ Jessica Oien, Attorney-in-Fact for Jonathan E. Lim 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did BOLD director Jonathan Lim receive on June 23, 2025?

Jonathan Lim received 24,000 stock options (right to buy) of BOLD common stock on June 23, 2025, with an exercise price of $1.03 per share.

What is the vesting schedule for BOLD director Jonathan Lim's stock options granted in June 2025?

The stock options vest in substantially equal monthly installments over 12 months following June 23, 2025. However, if BOLD's next annual stockholder meeting occurs before June 23, 2026, any remaining unvested portion will vest on the date of that meeting, subject to Lim's continued service on the board.

When do Jonathan Lim's BOLD stock options expire?

The stock options granted to Jonathan Lim expire on June 22, 2035, ten years after the grant date.

What is the exercise price of BOLD stock options granted to director Jonathan Lim in June 2025?

The exercise price of the stock options granted to Jonathan Lim is $1.03 per share.
BOUNDLESS BIO INC

NASDAQ:BOLD

BOLD Rankings

BOLD Latest News

BOLD Latest SEC Filings

BOLD Stock Data

26.42M
19.83M
11.4%
70.63%
0.34%
Biotechnology
Pharmaceutical Preparations
United States
SAN DIEGO